Clinical Report: Impact of Multidisciplinary Team Recommendations on Lung Cancer

Overview

This study evaluates the influence of Multidisciplinary Team (MDT) recommendations on treatment adherence and survival in lung cancer patients. Results indicate that MDT involvement significantly improves treatment completion rates and overall survival compared to non-MDT approaches.

Background

Lung cancer remains the leading cause of cancer-related mortality, necessitating complex management strategies tailored to individual patient profiles. The MDT model aims to enhance treatment decision-making by integrating expertise from various specialties, thereby improving patient outcomes. Understanding the impact of MDT recommendations on treatment adherence and survival is crucial for optimizing lung cancer care.

Data Highlights

Key Findings

• MDT group had a higher treatment completion rate (86.09% vs. 68.57%, P = 0.002).
• Lower treatment conversion rate in MDT group (19.13% vs. 39.05%, P = 0.001).
• Longer median overall survival in MDT group (45.21 months vs. 28.64 months, P < 0.001).
• Longer median progression-free survival in MDT group (19.80 months vs. 13.53 months, P < 0.001).
• MDT participation is an independent factor for improved OS (HR = 0.605, P = 0.009).
• Higher likelihood of treatment completion associated with MDT (OR = 3.438, P = 0.002).

Clinical Implications

The findings underscore the importance of MDT involvement in lung cancer management, suggesting that structured, collaborative decision-making can enhance treatment adherence and survival outcomes. Clinicians should prioritize MDT discussions to optimize initial treatment strategies for lung cancer patients.

Conclusion

The MDT model significantly improves treatment adherence and survival in lung cancer patients, highlighting its critical role in contemporary oncology practice. Further integration of MDT approaches is essential for enhancing patient care.

References

1. Atlantic Health System, Optimizing Outcomes: How Multidisciplinary Approaches Improve Prostate Cancer Survival Rates, 2023
2. The ASCO Post, Study Highlights Gaps Between Lung Cancer Treatment Recommendations and Real-World Use of Durvalumab, 2021
3. The ASCO Post, Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer, 2019
4. NICE, Diagnosis and staging | Lung cancer: diagnosis and management | Guidance, 2024
5. Journal of Gastrointestinal Surgery — The Role of Machine Learning in Enhancing Decision-Making within Oesophageal Cancer Multidisciplinary Teams
6. LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC
7. Multidisciplinary tumor boards (MTBs) and survival Outcomes
8. Diagnosis and staging | Lung cancer: diagnosis and management | Guidance | NICE